Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; Biopharmaceutical innovation and intellectual property policy issues.
Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.
Duration: January 1, 2008
to
present
General Issues: Copyright/Patent/Trademark , Health Issues , Trade (Domestic & Foreign)
Spending: about $13,189,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, Health & Human Services - Dept of (HHS), House of Representatives, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Richard Hertling
Staff Director & Chief Counsel, House Judiciary Committee; Acting Assistant AG, Office of Leg. Affairs, DoJ; Deputy Assistant AG, Office of Legal Policy, DoJ; Deputy CoS & Leg. Dir., Senator Lamar Alexander
Gabriel Neville
Chief of Staff, Congressman Joseph Pitts; Communications Director, Congressman Joseph Pitts; Press Secretary, Congressman Joseph Pitts; Special Assistant, Congressman Joseph Pitts
Jon Kyl
US Senator (1995-2013); US House Member (1987-1995)
US Senator (1995-2013; US House Member (1987-1995)
Aaron Cooper
Chief Counsel IP/Antitrust Law, Senate Judiciary Cmte; Counsel, Senator Sarbanes; Leg. Correspondent, Senator Lautenberg; Leg. Assistant, Representative Andrews
" "
Chief of Staff, Senator Peter Fitzgerald; Sr. Counsel, Senate Government Affairs; Chief Counsel, Senator Arlen Specter
Richard F. Kingham
Partner
Erika Lietzan
Partner
Marney L. Cheek
Special Counsel
Partner
Martin B. Gold
Partner
Alan Larson
Senior Advisor
Paul W. Schmidt
Partner
Michael S. Labson
Partner
Erika K. Lietzan
Partner
Paul W. Schmidt
Partner
John Veroneau
Deputy US Trade Rep., Genl Counsel & Asst. USTR for Congressional Affairs, Asst. Secy & DAS, Leg. Affairs, Dept. of Defense; Chief of Staff, Sen. Susan Collins; Leg. Dir., Sen. William Frist; Legal Asst., Leg. Counsel, Leg. Dir., Sen. William Cohen
Layth Elhassani
White House Off. Leg. Aff., Sp. Assist. to the President; Off. of Sen. Bennet, Leg. Dir.; House Comm. on Small Business, Oversight Counsel; Off. of Rep. Velazquez, Leg. Dir.; Off. of Sen. Cantwell, Leg. Counsel; Off. of Sen. Hollings, Legal Counsel
Gary Heimberg
n/a
Krista Carver
n/a
Jennifer Zachary
n/a
Richard Kingham
n/a
Tom Cosgrove
n/a
Andrew Lazerow
n/a
JENNIFER PLITSCH
n/a
Natalie Derzko
n/a
Michael Stern
n/a
Robert Long
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $190,000. The report was filed on April 22.
Original Filing: 301570041.xml
Lobbying Issues
Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; Biopharmaceutical innovation and intellectual property policy issues.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.
4th Quarter, 2023
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $180,000. The report was filed on Jan. 22.
Original Filing: 301537098.xml
Lobbying Issues
Induced infringement and generic drug labeling; Biopharmaceutical innovation and intellectual property policy issues.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Give Kids a Chance Act of 2023 (H.R. 3433); Affordable Prescriptions for Patients Act of 2023 (S. 150); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Promising Pathway Act (S. 1906/H.R.4408); Improving Efficiency to Increase Competition Act (H.R. 6684); Use code issues; Opioids regulation; Induced infringement and generic drug labeling; proposed amendments to the National Childhood Vaccine Injury Act and the Public Readiness and Emergency Preparedness (PREP) Act relating to compensation for injuries associated with covered vaccines.
3rd Quarter, 2023
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $170,000. The report was filed on Oct. 18, 2023.
Original Filing: 301504904.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S. 6); Discussion draft of the Primary Care and Health Workforce Act; Biosimilars; Drug compounding; Medication Affordability and Patient Integrity Act (S. 2780/H.R. 5429); Accelerated Approval; Orphan Cures Act (H.R. 5539); Pandemic and All-Hazards Preparedness Act reauthorization bills (S. 2333/H.R. 4220 and 4221).
2nd Quarter, 2023
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $140,000. The report was filed on July 20, 2023.
Original Filing: 301486428.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.
1st Quarter, 2023
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $140,000. The report was filed on April 20, 2023.
Original Filing: 301464808.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues; Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717).
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
Agencies Lobbied
Health & Human Services - Dept of (HHS) U.S. Senate
4th Quarter, 2022
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $100,000. The report was filed on Jan. 20, 2023.
Original Filing: 301437678.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues; Interagency Patent Coordination and Improvement Act of 2022 (S. 4430); Pride in Patent Ownership Act (S. 2774).
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Diverse and Equitable Participation in Clinical Trials Act (H.R. 6584); Advanced Research Project Agency-Health Act (H.R. 5585); America COMPETES Act of 2022 (H.R. 4521); Interagency Patent Coordination and Improvement Act of 2022 (S. 4430); Increasing Prescription Drug Competition Act (S. 4918); Consolidated Appropriations Act, 2023 (H.R. 2617); PASTEUR Act of 2021 (H.R. 3932/S. 2076); Biologics Competition Act of 2022 (H.R. 8877); Give Kids a Chance Act of 2022 (S. 4125/H.R. 6972); Orange Book listing issues; Bayh-Dole Act.
3rd Quarter, 2022
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $360,000. The report was filed on Oct. 20, 2022.
Original Filing: 301414412.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues; Interagency Patent Coordination and Improvement Act of 2022 (S. 4430); Patent Eligibility Restoration Act of 2022 (S. 4734); Patent Examination and Quality Improvement Act of 2022 (S. 4704).
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R.7667); Build Back Better Act (H.R. 5376); Diverse and Equitable Participation in Clinical Trials Act (H.R. 6584); Advanced Research Project Agency-Health Act (H.R. 5585); America COMPETES Act of 2022 (H.R. 4521); Interagency Patent Coordination and Improvement Act of 2022 (S. 4430); Food and Drug Administration Simple Reauthorization Act (S. 4535); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R. 6833); Inflation Reduction Act (H.R. 5376); Pediatric testing for drugs; Increasing Prescription Drug Competition Act (S. 4918).
2nd Quarter, 2022
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $510,000. The report was filed on July 20, 2022.
Original Filing: 301392443.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues; Interagency Patent Coordination and Improvement Act of 2022 (S. 4430).
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R.7667); Build Back Better Act (H.R. 5376); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032) ; Abbreviated approval pathway for biologics; 180-day exclusivity; Cures 2.0 Act (H.R. 6000); Accelerated Approval Integrity Act of 2022 (H.R. 6963); Give Kids a Chance Act (S.4215, H.R. 6972); Diverse and Equitable Participation in Clinical Trials Act (H.R. 6584); Accelerating Access for Patients Act of 2022 (H.R. 6996); FDA Modernization Act of 2021 (H.R. 2565) ; PREVENT Pandemics Act (S. 3799) Simplifying the Generic Drug Application Process Act (S. 1462); Advanced Research Project Agency-Health Act (H.R. 5585); America COMPETES Act of 2022 (H.R. 4521); Interagency Patent Coordination and Improvement Act of 2022 (S. 4430); Accelerated Approval Transparency Act (S. 4390); Modernizing the Accelerated Approval Pathway Act of 2022 (S. 4446 ); Biologics Market Transparency Act of 2022 (H.R. 7035); Bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (H.R. 7649); Affordable Prescriptions for Patients Act of 2021 (S. 1435); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 2884); Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 (H.R. 2873); Data Transparency and Drug Safety Act of 2022 (H.R. 6431).
1st Quarter, 2022
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $280,000. The report was filed on April 20, 2022.
Original Filing: 301367999.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues; Restoring the American Invents Act (S. 2891)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Build Back Better Act (H.R. 5376); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032); Abbreviated approval pathway for biologics; Orphan-drug exclusivity; Cures 2.0 Act (H.R. 6000); Accelerated Approval Integrity Act of 2022 (H.R. 6963); Give Kids a Chance Act (H.R. 6972); Diverse and Equitable Participation in Clinical Trials Act (H.R. 6584); Accelerating Access for Patients Act of 2022 (H.R. 6996); FDA Modernization Act of 2021 (H.R. 2565); PREVENT Pandemics Act (S. 3799) Simplifying the Generic Drug Application Process Act (S. 1462); Prescription Drug User Fee Act Reauthorization; Amendments to the Pediatric Research Equity Act; Right to try; Patent listing issues; Legislation to overrule Genus case; supply chain issues; Advanced Research Project Agency-Health Act (H.R. 5585); America COMPETES Act of 2022 (H.R. 4521)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $350,000. The report was filed on Jan. 20, 2022.
Original Filing: 301333731.xml
Lobbying Issues
Biopharmaceutical innovation and intellectual property policy issues; WTO TRIPS agreement; Restoring the American Invents Act (S. 2891); Countering Communist China Act (H.R. 4792); Second Look at Patents Act (S.1617); Conducting Legally Efficient Administration and Resolution of (CLEAR) Patents Act of 2021 (H.R. 5902).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Patent & Trademark Office (PTO)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Supply chain issues; Preserve Access to Affordable Generics and Biosimilars Act (S. 1428/ H.R. 2891); S. 1435, Affordable Prescriptions for Patients Act of 2021; H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; H.R. 2883, Stop Stalling Access to Affordable Medications; S. 1425, Stop STALLING Act; Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Build Back Better Act (H.R. 5376); Reduced Costs and Continued Cures Act (RCCCA) (H.R. 5260, H.R. 5237); drug pricing policy; Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act (S. 1209)/H.R. 3812); Give Kids a Chance Act (H.R. 5416); FDA Modernization Act of 2021 (H.R. 2565).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2021
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $190,000. The report was filed on Oct. 20, 2021.
Original Filing: 301312383.xml
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; WTO TRIPS agreement; Restoring the America Invents Act (S. 2891); Countering Communist China Act (H.R. 4792)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Clinical Trial Diversity; Preserve Access to Affordable Generics and Biosimilars Act (S. 1428/ H.R. 2891); S. 1435, Affordable Prescriptions for Patients Act of 2021; H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; Pediatric study requirements for drugs; Transparency of EUA Information; Induced Infringement; Biosimilarity; H.R. 2883, Stop Stalling Access to Affordable Medications; S. 1425, Stop STALLING Act; proposed amendments to the National Childhood Vaccine Injury Act; Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Build Back Better Act (H.R. 5376); drug pricing policy; drug quality issues; Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act (S. 1209/H.R. 3812)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $480,000. The report was filed on July 20, 2021.
Original Filing: 301290511.xml
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; WTO TRIPS agreement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Generic drug competition; Drug patent issues; Affordable Prescriptions for Patients Act of 2019 (S. 1416); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (H.R. 5133/H.R. 4398); H.R. 3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; Executive Order 13944 (List of Essential Medicines, Medical Countermeasures, and Critical Inputs); Executive Order 14001 on a Sustainable Public Health Supply Chain; Compulsory licensing; S.Res.625 - A resolution encouraging the Government and the people of the United States to "Buy American"; Executive Order 13922; Executive Order 13911; Executive Order 13938; Domestic manufacturing incentives; Potential amendments to PREP Act; Bayh-Dole Act; Learnings from Pandemic; Safe Authorization for Vaccines during Emergencies Act (S. 4427); Executive Order 13948 (Lowering Drug Prices by Putting America First); Advancing Americas Interests Act (H.R. 8037); Safeguarding American Innovation Act (S. 3997); Safe to Work Act (S. 4317); 340B drug discounts; Executive Order 13962 (Ensuring Access to United States Government COVID-19 Vaccines); Competition and Antitrust Law Enforcement Reform Act (S. 225); Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2020 (S. 4760/H.R. 8920);Protecting Our Pharmaceutical Supply Chain from China Act of 2020 (H.R. 6482); Part D noninterference; Return on Investment (ROI) Initiative for Unleashing American Innovation; 85 Fed. Reg. 76180; Suitability petitions; Securing America's Vaccines for Emergencies (SAVE) Act of 2020 (H.R. 6399/S. 3715); Pandemic Emergency Manufacturing Act of 2021 (S. 187); H.R.153 - Protecting Consumer Access to Generic Drugs Act of 2021; Lower Costs, More Cures Act (H.R. 19/ S. 3129); S.164 - Advancing Education on Biosimilars Act of 2021; Drug recalls; drug shortages; Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Medicare reimbursement of prescription drugs; S. 1435, Affordable Prescriptions for Patients Act of 2021; H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; H.R. 2387, STOP GAMES Act of 2019; H.R. 4384, Patient Safety and Drug Labeling Improvement; Transparency of EUA Information and FDA-State Information Sharing; Cures 2.0 Act Discussion Draft; H.R. 2883, Stop Stalling Access to Affordable Medications; S. 1425, Stop STALLING Act; Clinical Trial Diversity; S. 1644, Promising Pathway Act; Preserve Access to Affordable Generics and Biosimilars Act (S. 1428/ H.R. 2891); STOP Fentanyl Act of 2021 (S. 1457/H.R. 2366); S. 1508 - A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes; S. 1260, United States Innovation and Competition Act of 2021; H.R. 2731, Endless Frontier Act; draft Fiscal Year 2022 Labor, Health and Human Services, Education, and Related Agencies funding bill; draft legislation to amend provisions of the National Childhood Vaccination Injury Act to establish new criteria and procedures for covering vaccines in the Vaccine Injury Compensation Program; Country of origin labeling; Supply chain issues; Quality Systems; National Institute of Standards and Technologys (NIST) January 4, 2021 Notice of Proposed Rulemaking (NPRM) on 37 CFR Parts 401 and 404, the implementing regulations of the Bayh-Dole Act; Health Advanced Research Projects Agency (HARPA) proposal.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Communications regarding China's draft patent/regulatory linkage framework.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $380,000. The report was filed on April 20, 2021.
Original Filing: 301264277.xml
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; WTO TRIPS agreement adherence.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Generic drug competition; Drug patent issues; Affordable Prescriptions for Patients Act of 2019 (S. 1416); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (H.R. 5133/H.R. 4398); H.R. 3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; Executive Order 13944 (List of Essential Medicines, Medical Countermeasures, and Critical Inputs); Executive Order 14001 on a Sustainable Public Health Supply Chain; Compulsory licensing; Real world evidence; National Defense Authorization Act for Fiscal Year 2021 (S. 4049); S.Res.625 - A resolution encouraging the Government and the people of the United States to "Buy American"; Executive Order 13922; Executive Order 13911; Executive Order 13938; Domestic manufacturing incentives; Potential amendments to PREP Act; Bring Entrepreneurial Advancements To Consumers Here In North America Act (H.R. 6690); Bayh-Dole Act; Learnings from Pandemic; Safe Authorization for Vaccines during Emergencies Act (S.4427); Executive Order 13948 (Lowering Drug Prices by Putting America First); Advancing Americas Interests Act (H.R. 8037); Safeguarding American Innovation Act (S. 3997); Safe to Work Act (S. 4317); 340B drug discounts; Executive Order 13962 (Ensuring Access to United States Government COVID-19 Vaccines); antitrust reform proposals; Competition and Antitrust Law Enforcement Reform Act (S. 225); Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2020 (S. 4760/H.R. 8920); Lower Health Care Costs Act (S. 1895); Protecting Our Pharmaceutical Supply Chain from China Act of 2020 (H.R. 6482); Part D non-interference; Ensuring Innovation Act (S.1636); Return on Investment (ROI) Initiative for Unleashing American Innovation; 85 Fed. Reg. 76180; Suitability petitions; Securing America's Vaccines for Emergencies (SAVE) Act of 2020 (H.R. 6399/S. 3715); Pandemic Emergency Manufacturing Act of 2021 (S. 187); H.R.153 - Protecting Consumer Access to Generic Drugs Act of 2021; Lower Costs, More Cures Act (H.R. 19/ S. 3129); Fairness in Orphan Drug Exclusivity Act (S. 250/ H.R. 4712); S. 415 - A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity; S.164 - Advancing Education on Biosimilars Act of 2021; Preserve Access to Affordable Generics and Biosimilars Act (S. 64/HR 2375); Drug recalls; drug shortages; Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Medicare reimbursement of prescription drugs; Unnamed bill regarding FDA demand reporting with respect to drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Communications regarding China's draft patent/regulatory linkage framework and the state of patent enforcement generally.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $170,000. The report was filed on Jan. 21, 2021.
Original Filing: 301242970.xml
Lobbying Issues
Biopharmaceutical innovation and patent policy issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Generic drug competition; Drug patent issues; Affordable Prescriptions for Patients Act of 2019 (S. 1416); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (H.R. 5133/H.R. 4398); H.R. 3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; Executive Order 13944 (List of Essential Medicines, Medical Countermeasures, and Critical Inputs); Compulsory licensing; Real world evidence; National Defense Authorization Act for Fiscal Year 2021 (S. 4049); S.Res.625 - A resolution encouraging the Government and the people of the United States to "Buy American"; Executive Order 13922; Executive Order 13911; Executive Order 13938; Domestic manufacturing incentives; Potential amendments to PREP Act; Bring Entrepreneurial Advancements To Consumers Here In North America Act (H.R. 6690); Bayh-Dole Act; Prescription Drug User Fee Act reauthorization; Learnings from Pandemic; Safe Authorization for Vaccines during Emergencies Act (S.4427); Executive Order 13948 (Lowering Drug Prices by Putting America First); Advancing Americas Interests Act (H.R. 8037); Safeguarding American Innovation Act (S. 3997); Safe to Work Act (S. 4317); 340B drug discounts; Executive Order 13962 (Ensuring Access to United States Government COVID-19 Vaccines); antitrust reform proposals; Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2020 (S. 4760/H.R. 8920); Lower Health Care Costs Act (S. 1895); Orange Book Transparency Act of 2020 (H.R. 1503); Purple Book Continuity Act of 2020 (H.R. 1520); Consolidated Appropriations Act, 2021 (H.R. 133); Protecting Our Pharmaceutical Supply Chain from China Act of 2020 (H.R. 6482); Part D non-interference; Ensuring Innovation Act (S.1636); Return on Investment (ROI) Initiative for Unleashing American Innovation; 85 Fed. Reg. 76180.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $350,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222283.xml
Lobbying Issues
Biopharmaceutical innovation and patent policy issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); Generic drug competition; Drug patent issues; Affordable Prescriptions for Patients Act of 2019 (S. 1416); Preserve Access to Affordable Generics and Biosimilars Act (H.R.2375); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (H.R. 5133/H.R. 4398); H.R.3666 - STRONGER Patents Act of 2019, H.R.19 - Lower Costs, More Cures Act of 2019, Pharmaceutical Independence Long-Term Readiness Reform Act (H.R. 4710); H.R. 3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; Lowering Prescription Drug Prices for Americas Seniors and Families Act (S. 3384); Second Look at Drug Patents Act of 2019 (S. 1617); Recall Unsafe Drugs Act of 2020 (H.R. 5578); Executive Order 13944; Compulsory licensing; Strengthening Innovation in Medicare and Medicaid Act (H.R. 5741), No Ban Act (H.R. 2214/S. 1123); Benefit and Payment Parameters; Notice Requirement for Non-Federal Governmental Plans (85 Fed. Reg. 7088); Medical Supply Chain Security Act (S. 3343); Strengthening America's Supply Chain and National Security Act (S. 3538 / H.R.6393); Drug recalls, registration and listing, inspections, expiration dating and shortages, and supply chain issues; Real world evidence; Presidential Proclamation 10052 of June 22, 2020; Taxpayer Research and Coronavirus Knowledge Act of 2020 (H.R.7288); Make Medications Affordable by Preventing Pandemic Pricegouging Act of 2020 (H.R.7296); Strategic National Stockpile; National Defense Authorization Act for Fiscal Year 2021 (S. 4049); Endless Frontier Act (H.R.6978 / S. 3832); S.Res.625 - A resolution encouraging the Government and the people of the United States to "Buy American"; Creating Helpful Incentives to Produce Semiconductors (CHIPS) for America Act (S.3933); Securing America From Epidemics Act (H.R.6334); The Heroes Act (H.R.6800); Securing America's Vaccines for Emergencies (H.R. 6399/S. 3715); Executive Order 13922; Executive Order 13911; Executive Order 13938; Domestic manufacturing incentives; Potential amendments to PREP Act; Bring Entrepreneurial Advancements To Consumers Here In North America Act (H.R. 6690); Bayh-Dole Act; Pharmaceutical Accountability, Responsibility, and Transparency Act (S.3781); Prescription Drug User Fee Act reauthorization; Learnings from Pandemic; Safe Authorization for Vaccines during Emergencies Act (S.4427); Potential Amendments to the Rules of Practice for Trials Before the Patent Trial and Appeal Board; Executive Order 13948; Advancing Americas Interests Act (H.R. 8037); Safeguarding American Innovation Act (S. 3997); Safe to Work Act (S. 4317); 340B drug discounts.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $420,000. The report was filed on July 20, 2020.
Original Filing: 301199424.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Medicare Part D coverage gap closure; USMCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); Generic drug competition; Drug patent issues; Lower Health Care Costs Act of 2019 (S. 1895); STOP Stalling Act (S. 1224); Affordable Prescriptions for Patients Act of 2019 (S. 1416); Preserve Access to Affordable Generics and Biosimilars Act (H.R.2375); Protecting Access to Biosimilars Act of 2019 (H.R.2011/S. 1140); Drug importation; State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 (H.R. 2038); Transparent Drug Pricing Act of 2019 (S.977); Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046); Medicare Prescription Drug Price Negotiation Act of 2019 (H.R. 275); Medicare Drug Price Negotiation Act (H.R. 448); Lower Drug Costs Now Act of 2019 (H.R. 3); Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 (S.476); Fair Care Act of 2019 (H.R.1332); Prescription Drug Pricing Reduction Act of 2019 (S. 2543); Competition Prescription Act of 2019 (H.R. 3947); Fixing Global Freeloading Act (H.R. 2209); National Defense Authorization Act for Fiscal Year 2020 (S.1790); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (HR 5133/HR 4398); STOP GAMES Act of 2019 (HR 2387); H.R.3666 - STRONGER Patents Act of 2019, H.R.19 - Lower Costs, More Cures Act of 2019, Pharmaceutical Independence Long-Term Readiness Reform Act (HR 4710); H.R. 3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; Purple Book Continuity Act of 2019 (H.R. 1520); Biologic Patent Transparency Act (S. 659); Orange Book Transparency Act of 2019 (H.R. 1503); Prescription Drug Affordability and Access Act (S. 3166); Biosimilars user fees legislation; Lowering Prescription Drug Prices for Americas Seniors and Families Act (S. 3384); Anticompetitive Exclusionary Conduct Prevention Act of 2020 (S. 3426); Second Look at Drug Patents Act of 2019 (S. 1617); Priority review vouchers; MODERN Labeling Act of 2020 (HR 5668); Recall Unsafe Drugs Act of 2020 (HR 5578); Buy American Executive Order; Compulsory licensing; Strengthening Innovation in Medicare and Medicaid Act (H.R. 5741), No Ban Act (H.R. 2214/S. 1123); Benefit and Payment Parameters; Notice Requirement for Non-Federal Governmental Plans (85 Fed. Reg. 7088); Medical Supply Chain Security Act (S. 3343); Strengthening America's Supply Chain and National Security Act (S. 3538 / H.R.6393) Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), Drug recalls, registration and listing, expiration dating and shortages, and supply chain issues; Real world evidence; Presidential Proclamation 10052 of June 22, 2020; Taxpayer Research and Coronavirus Knowledge Act of 2020 (H.R.7288); Biosimilars user fee legislation; Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020 (HR 6260/S.3545); Make Medications Affordable by Preventing Pandemic Pricegouging Act of 2020 (H.R.7296); Strategic National Stockpile; Data Sharing; National Defense Authorization Act for Fiscal Year 2021 (HR 4049); Endless Frontier Act (H.R.6978 / S. 3832); S.Res.625 - A resolution encouraging the Government and the people of the United States to "Buy American"; Creating Helpful Incentives to Produce Semiconductors (CHIPS) for America Act (S.3933); Securing America From Epidemics Act (H.R.6334); The Heroes Act (H.R.6800); Securing America's Vaccines for Emergencies (HR 6399/S. 3715); Executive Order 13922; Executive Order 13911; Executive Order 13922; Domestic manufacturing incentives; Potential amendments to PREP Act; Bring Entrepreneurial Advancements To Consumers Here In North America Act (H.R. 6690); Protecting Americans with Preexisting Conditions Act of 2019 (H.R. 986); Bayh-Dole Act; TM Act of 2020 (S.3449 / HR 6196); Pharmaceutical Accountability, Responsibility, and Transparency Act (S.3781); Protecting Our Pharmaceutical Supply Chain from China Act of 2020 (S.3537)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
WTO and USMCA enforcement(formerly NAFTA); US Trade negotiations.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2020
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $260,000. The report was filed on April 20, 2020.
Original Filing: 301177375.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Medicare Part D coverage gap closure; USMCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); Generic drug competition; Drug patent issues; Proposed rule on rebate safe Harbor (84 Fed. Reg. 2340); Lower Health Care Costs Act of 2019 (S. 1895); STOP Stalling Act (S. 1224); Affordable Prescriptions for Patients Act of 2019 (S. 1416); Preserve Access to Affordable Generics and Biosimilars Act (H.R.2375); Drug importation; State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 (H.R. 2038); Transparent Drug Pricing Act of 2019 (S.977); Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 (S. 2161); Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046); Direct to consumer advertising; Medicare Prescription Drug Price Negotiation Act of 2019 (H.R. 275); Medicare Drug Price Negotiation Act (H.R. 448); Lower Drug Costs Now Act of 2019 (H.R. 3); Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 (S.476); Fair Care Act of 2019 (H.R.1332); Prescription Drug Pricing Reduction Act of 2019 (S. 2543); Competition Prescription Act of 2019 (H.R. 3947); Fixing Global Freeloading Act (H.R. 2209); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (HR 5133/HR 4398); STOP GAMES Act of 2019 (HR 2387);; H.R.3666 - STRONGER Patents Act of 2019, H.R.19 - Lower Costs, More Cures Act of 2019, Pharmaceutical Independence Long-Term Readiness Reform Act (HR 4710); H.R. 3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; Purple Book Continuity Act of 2019 (H.R. 1520); Biologic Patent Transparency Act (S. 659); Conditional Approval Act (S. 3133); Fairness in Orphan Drug Exclusivity Act (H.R. 4712 / S. 3271); Orange Book Transparency Act of 2019 (H.R. 1503); Prescription Drug Affordability and Access Act (S. 3166); Biosimilars user fees legislation; Lowering Prescription Drug Prices for Americas Seniors and Families Act (S. 3384); Anticompetitive Exclusionary Conduct Prevention Act of 2020 (S. 3426); Second Look at Drug Patents Act of 2019 (S. 1617); Priority review vouchers; MODERN Labeling Act of 2020 (HR 5668); CARES Act (HR 748/S. 3548); Recall Unsafe Drugs Act of 2020 (HR 5578); Buy American Executive Order; Compulsory licensing; Strengthening Innovation in Medicare and Medicaid Act (H.R. 5741), No Ban Act (H.R. 2214/S. 1123); Benefit and Payment Parameters; Notice Requirement for Non-Federal Governmental Plans (85 Fed. Reg. 7088); Mitigating Emergency Drug Shortages Act (MEDS Act) (S. 2723); Medical Supply Chain Security Act (S. 3343); Strengthening America's Supply Chain and National Security Act (S. 3538) Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), Drug recalls, registration and listing, shortages, and supply chain reporting; Strategic National Stockpile.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
WTO and NAFTA enforcement.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2019
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $180,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124501.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Medicare Part D coverage gap closure; USMCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); CREATES Act of 2019 (HR 965/S. 340); Generic drug competition; Drug patent issues; Proposed rule on rebate safe Harbor (84 Fed. Reg. 2340); Lower Health Care Costs Act of 2019 (S. 1895); STOP Stalling Act (S. 1224); Affordable Prescriptions for Patients Act of 2019 (S. 1416); Preserve Access to Affordable Generics and Biosimilars Act (H.R.2375); Protecting Access to Biosimilars Act of 2019 (H.R.2011/S. 1140); Drug importation; State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 (H.R. 2038); Transparent Drug Pricing Act of 2019 (S.977); Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 (S. 2161); Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046); Affordable Insulin Approvals Now Act (S. 2103); Direct to consumer advertising; Medicare Prescription Drug Price Negotiation Act of 2019 (H.R. 275); Medicare Drug Price Negotiation Act (H.R. 448); Lower Drug Costs Now Act of 2019 (H.R. 3); Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 (S.476); Fair Care Act of 2019 (H.R.1332); Prescription Drug Pricing Reduction Act of 2019 (S. 2543); Competition Prescription Act of 2019 (H.R. 3947); Fixing Global Freeloading Act (H.R. 2209); National Defense Authorization Act for Fiscal Year 2020 (S.1790); Further Consolidated Appropriations Act, 2020 (H.R.1865); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (HR 5133); Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (HR 4398); STOP GAMES Act of 2019 (HR 2387); H.R. 5198 - Patients' Right to Know Their Medication Act of 2019; 30-month stays; H.R.3666 - STRONGER Patents Act of 2019, H.R.19 - Lower Costs, More Cures Act of 2019, Pharmaceutical Independence Long-Term Readiness Reform Act (HR 4710); H.R. 3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $340,000. The report was filed on Oct. 21, 2019.
Original Filing: 301075261.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Medicare Part D coverage gap closure; USMCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); BLOCKING Act of 2019 (H.R. 938); Orange Book Transparency Act of 2019 (H.R. 1503); Purple Book Continuity Act of 2019 (H.R. 1520); CREATES Act of 2019 (HR 965/S. 340); Biologic Patent Transparency Act (S. 659); Generic drug competition; Drug patent issues; Proposed rule on rebate safe Harbor (84 Fed. Reg. 2340); Lower Health Care Costs Act of 2019 (S. 1895); STOP Stalling Act (S. 1224); Affordable Prescriptions for Patients Act of 2019 (S. 1416); Preserve Access to Affordable Generics and Biosimilars Act (H.R.2375); A bill to establish a process for updating the labeling of certain drugs with outdated labeling (S.1897); Protecting Access to Biosimilars Act of 2019 (H.R.2011/S. 1140); TERM Act. (H.R. 3199); Drug importation; State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 (H.R. 2038); Transparent Drug Pricing Act of 2019 (S.977); Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 (S. 2161); Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046); Preserving Access to Cost Effective Drugs Act (S. 440); Affordable Insulin Approvals Now Act (S. 2103); Direct to consumer advertising; Medicare Prescription Drug Price Negotiation Act of 2019 (H.R. 275); Medicare Drug Price Negotiation Act (H.R. 448); Lower Drug Costs Now Act of 2019 (H.R. 3); Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 (S.476); Fair Care Act of 2019 (H.R.1332); Prescription Drug Pricing Reduction Act of 2019 (S. 2543); Competition Prescription Act of 2019 (H.R. 3947); Fixing Global Freeloading Act (H.R. 2209); National Defense Authorization Act for Fiscal Year 2020 (S.1790); Patient drug labeling.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2019
COVINGTON & BURLING LLP amended a lobbying report for representation of PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. in Q22019 on Aug. 8, 2019.
Original Filing: 301060796.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Medicare Part D coverage gap closure.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); BLOCKING Act of 2019 (H.R. 938); Orange Book Transparency Act of 2019 (H.R. 1503); Purple Book Continuity Act of 2019 (H.R. 1520); CREATES Act of 2019 (HR 965/S. 340); Biologic Patent Transparency Act (S. 659); Generic drug competition; Drug patent issues; Proposed rule on rebate safe Harbor (84 Fed. Reg. 2340); Lower Health Care Costs Act of 2019 (S. 1895); STOP Stalling Act (S. 1224); Affordable Prescriptions for Patients Act of 2019 (S. 1416); Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209); Preserve Access to Affordable Generics and Biosimilars Act (H.R.2375); A bill to establish a process for updating the labeling of certain drugs with outdated labeling (S.1897); Protecting Access to Biosimilars Act of 2019 (H.R.2011/S. 1140); Second Look at Drug Patents Act of 2019 (S.1617); TERM Act. (H.R. 3199); Drug importation; State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 (H.R. 2038); Transparent Drug Pricing Act of 2019 (S.977); Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2017 (S. 2022); Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2019
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $430,000. The report was filed on July 22, 2019.
Original Filing: 301057308.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Medicare Part D coverage gap closure.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); BLOCKING Act of 2019 (H.R. 938); Orange Book Transparency Act of 2019 (H.R. 1503); Purple Book Continuity Act of 2019 (H.R. 1520); CREATES Act of 2019 (HR 965/S. 340); Biologic Patent Transparency Act (S. 659); Generic drug competition; Drug patent issues; Proposed rule on rebate safe Harbor (84 Fed. Reg. 2340); Lower Health Care Costs Act of 2019 (S. 1895); STOP Stalling Act (S. 1224); Affordable Prescriptions for Patients Act of 2019 (S. 1416); Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209); Preserve Access to Affordable Generics and Biosimilars Act (H.R.2375); A bill to establish a process for updating the labeling of certain drugs with outdated labeling (S.1897); Protecting Access to Biosimilars Act of 2019 (H.R.2011/S. 1140); Second Look at Drug Patents Act of 2019 (S.1617); TERM Act. (H.R. 3199); Drug importation; State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 (H.R. 2038); Transparent Drug Pricing Act of 2019 (S.977); Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2017 (S. 2022); Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $250,000. The report was filed on April 22, 2019.
Original Filing: 301037708.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Medicare Part D coverage gap closure.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 64); Regulatory exclusivity; Drug pricing; citizen petitions; Medicare Part B international reference pricing; Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); BLOCKING Act of 2019 (H.R. 938);Orange Book Transparency Act of 2019 (H.R. 1503); Purple Book Continuity Act of 2019 (H.R. 1520); CREATES Act of 2019 (HR 965/S. 340); Biologic Patent Transparency Act (S. 659); Generic drug competition; Drug patent issues; Competitive DRUGS Act of 2019 (HR 1344); FAIR Generics Act (HR 1506); Proposed rule on rebate safe harbor (84 Fed. Reg. 2340); PHAIR Pricing Act of 2019 (HR 1034); Accelerated Drug Approval for Prescription Therapies Act (ADAPT Act) (S.658).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2018
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $320,000. The report was filed on Jan. 22, 2019.
Original Filing: 301016168.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Protecting Medicare from Executive Action Act of 2017 (S. 251); STRONGER Patents Act (S.1390)(HR 5340); Medicare Part D coverage gap closure.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Preserve Access to Affordable Generics Act (S. 124); Regulatory exclusivity; Improving Access To Affordable Prescription Drugs Act (S. 771/H.R. 1776); Drug pricing; SUPPORT for Patients and Communities Act (H.R. 6); Biosimilars Competition Act of 2018 (H.R. 6478); Patient Right to Know Drug Prices Act (S. 2554/H.R. 6143); Medicare Negotiation and Competitive Licensing Act of 2018 (H.R. 6505); Making Objective Drug Evidence Revisions for New (MODERN) Labeling Act (S. 3519); citizen petitions; Medicare Part B international reference pricing; Hatch-Waxman Integrity Act of 2018 (S. 3738/H.R. 7251); Affordable Drug Manufacturing Act of 2018 (H.R. 7348/S. 3775); Preserve Access to Affordable Generics and Biosimilars Act (S. 3792); Direct-to-consumer pharmaceutical advertising.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
United States-Mexico-Canada Agreement (USMCA)
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2018
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $270,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990148.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Protecting Medicare from Executive Action Act of 2017 (S. 251); STRONGER Patents Act (S.1390)(HR 5340); Medicare Part D coverage gap closure.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); The Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act (i.e., the "SCREEN Act")(H.R. 5228); Opioid Crisis Response Act of 2018 (S. 2680); Expanding Access to Low Cost Generic Drugs Act (S. 2476); Preserve Access to Affordable Generics Act (S. 124); Regulatory exclusivity; Improving Access To Affordable Prescription Drugs Act (S. 771/H.R. 1776); Comprehensive Addiction Resources Emergency Act (CARE Act)(S. 2700/HR 5545); SOUND Disposal and Packaging Act (HR 5687); Long-Term Opioid Efficacy Act of 2018 (HR 5811); SAFETY Act of 2018 (H.R. 5803); Drug pricing; H.R. 5752, the Stop Illicit Drug Importation Act of 2018; proposed legislation regarding tableting and encapsulating opioid products; Drug Importation; CREATES Act (HR 2212/S. 974; 340B issues; SUPPORT for Patients and Communities Act (H.R. 6), Biosimilars Competition Act of 2018 (H.R. 6478), Patient Right to Know Drug Prices Act (S. 2554/H.R. 6143), Re-Valuing Anti-Microbial Products Act of 2018 (H.R. 6294), Medicare Negotiation and Competitive Licensing Act of 2018 (H.R. 6505), Making Objective Drug Evidence Revisions for New (MODERN) Labeling Act (S. 3519), citizen petitions
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $290,000. The report was filed on July 20, 2018.
Original Filing: 300976637.xml
Lobbying Issues
Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Protecting Medicare from Executive Action Act of 2017 (S. 251); STRONGER Patents Act (S.1390); Medicare Part D coverage gap closure.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); The Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act (i.e., the "SCREEN Act")(H.R. 5228); Opioid Crisis Response Act of 2018 (S. 2680); Expanding Access to Low Cost Generic Drugs Act (S. 2476); Preserve Access to Affordable Generics Act (S. 124); Regulatory exclusivity; Improving Access To Affordable Prescription Drugs Act (S. 771/H.R. 1776); Legislation on drug labeling; Comprehensive Addiction Resources Emergency Act (CARE Act)(S. 2700/HR 5545); SOUND Disposal and Packaging Act (HR 5687); Biologics patent settlements; Long-Term Opioid Efficacy Act of 2018 (HR 5811); SAFETY Act of 2018 (H.R. 5803); Insulin pricing; H.R. 5752, the Stop Illicit Drug Importation Act of 2018; proposed legislation regarding tableting and encapsulating opioid products; Drug Importation; Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act (HR 5247/S. 204; CREATES Act (HR 2212/S. 974)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2018
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $310,000. The report was filed on April 18, 2018.
Original Filing: 300948031.xml
Lobbying Issues
Drug importation; Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Bayh-Dole march-in rights policy issues; Independent Payment Advisory Board - Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849); Approving the Discontinuation of the Process for Consideration and Automatic Implementation of the Annual Proposal of the Independent Medicare Advisory Board under Section 1899A of the Social Security Act(H.J. Res. 51); Protecting Medicare from Executive Action Act of 2017 (S. 251); A Joint Resolution Approving the Discontinuation of the Process for Consideration and Automatic Implementation of the Annual Proposal of the Independent Medicare Advisory Board under Section 1899A of the Social Security Act(S.J. Res. 16); STRONGER Patents Act (S.1390)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (H.R. 5247); Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051) and CREATES Act (H.R. 2212/S. 974); Synthetic Drug Control Act of 2017 (H.R. 1732); Modernizing Drug Enforcement Act of 2018 (H.R. 5298) The Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 (H.R. 5202); The Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act (i.e., the "SCREEN Act")(H.R. 5228); Opioid Crisis Response Act of 2018; House opioids legislation discussion drafts on FDA Long-term Efficacy, FDA Misuse/Abuse, FDA Packaging and Disposal, FDA Accelerated Approval and Breakthrough Therapy Status, and FDA and International Mail; Drug importation; Expanding Access to Low Cost Generic Drugs Act (S. 2476); Preserve Access to Affordable Generics Act (S. 124); 180-day exclusivity; Over-the-Counter Drug Safety, Innovation, and Reform Act (S. 2315); Improving Access To Affordable Prescription Drugs Act (S. 771/H.R. 1776); Legislation on drug labeling.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $200,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934514.xml
Lobbying Issues
Drug importation; Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Bayh-Dole march-in rights policy issues; Independent Payment Advisory Board - Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849); Approving the Discontinuation of the Process for Consideration and Automatic Implementation of the Annual Proposal of the Independent Medicare Advisory Board under Section 1899A of the Social Security Act(H.J. Res. 51); Protecting Medicare from Executive Action Act of 2017 (S. 251); A Joint Resolution Approving the Discontinuation of the Process for Consideration and Automatic Implementation of the Annual Proposal of the Independent Medicare Advisory Board under Section 1899A of the Social Security Act(S.J. Res. 16); STRONGER Patents Act (S.1390)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (S. 204); Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051) and CREATES Act (H.R. 2212/S. 974); Synthetic Drug Control Act of 2017 (H.R. 1732); Pandemic All-Hazards Preparedness Reauthorization Act of 2017; Opioid scheduling not associated with any particular bill.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $330,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915654.xml
Lobbying Issues
Drug importation; Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Bayh-Dole march-in rights policy issues; Independent Payment Advisory Board - Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849); Approving the Discontinuation of the Process for Consideration and Automatic Implementation of the Annual Proposal of the Independent Medicare Advisory Board under Section 1899A of the Social Security Act(H.J. Res. 51); Protecting Medicare from Executive Action Act of 2017 (S. 251); A Joint Resolution Approving the Discontinuation of the Process for Consideration and Automatic Implementation of the Annual Proposal of the Independent Medicare Advisory Board under Section 1899A of the Social Security Act(S.J. Res. 16)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (S. 204); Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); Food and Drug Administration Reauthorization Act (S. 934/H.R. 2430); Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051) and CREATES Act (H.R. 2212/S. 974); Affordable and Safe Prescription Drug Importation Act (S. 469/H.R. 1245); RACE for Children Act (S. 456/H.R. 1231); Safe and Affordable Drugs from Canada Act of 2017 (S. 92); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (H.R.3268); Synthetic Drug Control Act of 2017 (H.R. 1732); Make America Secure and Prosperous Appropriations Act, 2018 (H.R. 3354); Anticipated Fiscal Year 2017 Senate Budget Reconciliation Bill
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $430,000. The report was filed on July 20, 2017.
Original Filing: 300895538.xml
Lobbying Issues
Drug importation; IPAB; Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Bayh-Dole march-in rights policy issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Trickett Wendler Right to Try Act of 2017 (S.204); Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); Food and Drug Administration Reauthorization Act (S. 934/H.R. 2430); Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 (H.R. 2025); Medical Product Communications Act of 2017 (H.R. 1705); S. Amendment 178 to S. Con. Res. 3 (on importation of drugs from Canada); Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051) and CREATES Act (H.R. 2212/S. 974); Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act); Affordable and Safe Prescription Drug Importation Act (S. 469/H.R. 1245); RACE for Children Act (S. 456/H.R. 1231); Safe and Affordable Drugs from Canada Act of 2017 (S. 92); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (H.R.3268); Preserving Patient Access to Compounded Medications Act of 2017 (H.R. 2781)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Identify trade enforcement options; Develop model trade treaty text
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2017
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $460,000. The report was filed on April 20, 2017.
Original Filing: 300874499.xml
Lobbying Issues
CMMI Part B demonstration; Implementation issues related to 21st Century Cures; Patent Litigation Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Trickett Wendler Right to Try Act of 2017 (S.204); Biosimilar User Fee Act; Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051) and CREATES Act (S. 3056); Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act); Affordable and Safe Prescription Drug Importation Act (S. 469); RACE for Children Act (S. 456/H.R. 1231); Prescription Drug User Fee Act; Improving Access To Affordable Prescription Drugs Act (S.771/H.R. 1776); Preserve Access to Affordable Generics Act (S. 124); American Health Care Act, section Tax on prescription medications; Recall Unsafe Drugs Act of 2017 (H.R. 1108)
Lobbying Issues
Identify trade enforcement options; Develop model trade treaty text
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2016
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $230,000. The report was filed on Jan. 23, 2017.
Original Filing: 300854712.xml
Lobbying Issues
CMMI Part B demonstration; 21st Century Cures; Patent Litigation Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2016
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $180,000. The report was filed on Oct. 18, 2016.
Original Filing: 300830966.xml
Lobbying Issues
Legislative Drug Pricing Issues; CMMI Part B demonstration; Integrity of the Part D program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2016
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $220,000. The report was filed on July 20, 2016.
Original Filing: 300816869.xml
Lobbying Issues
Legislative Drug Pricing Issues; CMMI Part B demonstration; Integrity of the Part D program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Promoting Biomedical Research and Public Health for Patients Act
1st Quarter, 2016
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $190,000. The report was filed on April 20, 2016.
Original Filing: 300801781.xml
Lobbying Issues
Legislative Drug Patent and Pricing Issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
REGROW Act (H.R.4762); and Prescription Drug User Fee Act.
4th Quarter, 2015
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $250,000. The report was filed on Jan. 20, 2016.
Original Filing: 300782188.xml
Type of Issue
Copyright/Patent/Trademark Health Issues
3rd Quarter, 2015
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $260,000. The report was filed on Oct. 19, 2015.
Original Filing: 300757453.xml
Lobbying Issues
Drug Legislation Issues.
Trade Secret Issues.
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $200,000. The report was filed on July 20, 2015.
Original Filing: 300743050.xml
Lobbying Issues
Patent Reform Legislation, Senate Bill 1137
Agencies Lobbied
U.S. Senate Patent & Trademark Office (PTO)
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $160,000. The report was filed on April 14, 2015.
Original Filing: 300715430.xml
Lobbying Issues
Drug Legislation Issues.
Trade Secret Issues.
4th Quarter, 2014
In Q4, COVINGTON & BURLING LLP did no lobbying for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. . The report was filed on Jan. 20, 2015.
Original Filing: 300704637.xml
3rd Quarter, 2014
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $70,000. The report was filed on Oct. 13, 2014.
Original Filing: 300675405.xml
Lobbying Issues
Drug Legislation Issues
Trade Secret Issues
2nd Quarter, 2014
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $40,000. The report was filed on July 21, 2014.
Original Filing: 300665330.xml
Lobbying Issues
Drug Legislation Issues
Trade Secret Issues
1st Quarter, 2014
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $20,000. The report was filed on April 21, 2014.
Original Filing: 300646322.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Biosimilars
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $15,000. The report was filed on Jan. 8, 2014.
Original Filing: 300611974.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Biosimilars
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $90,000. The report was filed on Oct. 17, 2013.
Original Filing: 300596579.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Biosimilars
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $90,000. The report was filed on July 19, 2013.
Original Filing: 300577494.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $30,000. The report was filed on April 22, 2013.
Original Filing: 300561998.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $40,000. The report was filed on Jan. 11, 2013.
Original Filing: 300527666.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $50,000. The report was filed on Oct. 15, 2012.
Original Filing: 300506577.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $240,000. The report was filed on July 19, 2012.
Original Filing: 300492815.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $140,000. The report was filed on April 20, 2012.
Original Filing: 300470169.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $190,000. The report was filed on Jan. 20, 2012.
Original Filing: 300447948.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $160,000. The report was filed on Oct. 19, 2011.
Original Filing: 300421178.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $80,000. The report was filed on July 20, 2011.
Original Filing: 300403649.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $124,000. The report was filed on April 20, 2011.
Original Filing: 300377574.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $90,000. The report was filed on Jan. 18, 2011.
Original Filing: 300340999.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $100,000. The report was filed on Oct. 19, 2010.
Original Filing: 300319381.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $30,000. The report was filed on Aug. 3, 2010.
Original Filing: 300306043.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $100,000. The report was filed on April 20, 2010.
Original Filing: 300268341.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $100,000. The report was filed on Jan. 5, 2010.
Original Filing: 300227378.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $80,000. The report was filed on Oct. 20, 2009.
Original Filing: 300217123.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $160,000. The report was filed on July 17, 2009.
Original Filing: 300182482.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $130,000. The report was filed on April 16, 2009.
Original Filing: 300150944.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $240,000. The report was filed on Jan. 21, 2009.
Original Filing: 300128707.xml
Lobbying Issues
Follow-On Biologics
Drug Legislation Issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $190,000. The report was filed on Oct. 17, 2008.
Original Filing: 300097043.xml
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $130,000. The report was filed on July 21, 2008.
Original Filing: 300078339.xml
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, COVINGTON & BURLING LLP lobbied for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA, INC. , earning $170,000. The report was filed on April 21, 2008.
Original Filing: 300051377.xml
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate